Table 1. VPC prostate cancer cohort clinical details.
| VPC ID | Tumour or Benign | Age at Dx | PSA at Dx | Gleason score | PSA recurrence months to | Follow up (months post-surgery) | ETS status |
|---|---|---|---|---|---|---|---|
| VPCT1 | T | 74 | 2.1 | 9 (4+5) N | 123 | ERG | |
| VPCT4 | T | 65 | 17.0 | 9 (4+5) | Y (nrn) | 71 | negative |
| VPCB4 | B | n/a | |||||
| VPCT5 | T | 71 | 8.0 | 8 (4+4) | Y (34) | 94 | ERG |
| VPCT11 | T | 65 | 8.1 | 7 (3+4) | N | 83 | ERG |
| VPCB11 | B | n/a | |||||
| VPCT12 | T | 64 | 1.37 | 9 (4+5) | Y (30) | 66 | ETV1 |
| VPCT13 | T | 57 | 31.0 | 9 (4+5) | Y (28) | 48 | ERG |
| VPCB13 | B | n/a | |||||
| VPCT15 | T | 69 | 15.07 | 7 (4+3) | Y (nrn) | 41 | negative |
| VPCT16 | T | 45 | 6.3 | 10 (5+5) | Y (3) | 45 | negative |
| VPCT18 | T | 59 | 10.1 | 8 (4+4) | Y (15) | 46 | ETV1 |
| VPCT19 | T | 53 | 7.7 | 8 (4+4) | N | 18 (LTFU) | ERG |
| VPCT21 | T | 70 | 65.3 | 9 (4+5) | Y (nrn) | 5 (LTFU) | ERG |
| VPCT22 | T | 47 | 4.2 | 9 (5+3) | Y (55) | 59 | ERG |
| VPCT23 | T | 63 | 22 | 10 (5+5) | Y (nrn) | 40 | ETV1 |
| VPCT24 | T | 64 | 17 | 9 (5+4) | Y (nrn) | 49 | ERG |
The prostate cancer cohort of the Vancouver Prostate Centre (VPC) consisted of 14 untreated primary tumours and 3 matched benign prostate tissues [44]. Abbreviations: T, tumour; B, Benign; Dx, diagnosis; PSA, prostate specific antigen; nrn, never reached nadir; N, no; Y, yes; LTFU, lost to follow-up. There were no differences in stromal content across the cohort based on comparisons of desmin and vimentin expression (fibroblasts) [44].